Sen. Wyden calls Biogen's Alzheimer's drug price 'unconscionable' in tweet

Latest News & Information for the U.S. Senate

Sen. Ron Wyden (D-Ore.) is criticizing Biogen (NASDAQ:BIIB) for its estimated $56K annual price tag for its newly approved Alzheimer's treatment …

Full story here.

Originally published 2021-06-08 09:46:15 — seekingalpha.com

Leave a Reply